Skip to main content
Secondary Faculty

Maitreyi Mazumdar

Associate Professor in the Department of Environmental Health

Environmental Health, Harvard T.H. Chan School of Public Health

Departments

Department of Environmental Health

Other Positions

Associate Professor of Neurology

Neurology-Boston Children's Hospital, Harvard Medical School

Biography

I am a pediatric neurologist and translational researcher at Boston Children's Hospital (BCH). My scholarship of discovery focuses on identifying potentially remediable environmental causes of disease, defining the biological pathways through which exposures affect health, and translating those findings into clinical practice and policy. A distinguishing feature of my program is its full translational scope: I connect clinical and population studies with molecular investigation, experimental models, clinical trials, and health services research.

My best-known contribution is identifying that arsenic exposure reduces the protection folic acid gives against neural tube defects. This work takes place in Bangladesh, where tens of millions of people drink arsenic-contaminated water, a situation the World Health Organization calls the "largest mass poisoning of a population in history." Since my promotion to Associate Professor in 2018, I have advanced this work through genetic and epigenetic investigations, a clinical trial of high-dose folic acid, and a decision analysis that changed national prevention policy.

Folic acid is the foundation of neural tube defect prevention, yet it does not prevent every case, and the mechanisms underlying its effect remain unknown. I asked whether arsenic weakens folic acid's protection. This hypothesis was plausible because arsenic metabolism depends on the same folate-related pathways that regulate embryonic development; arsenic also induces neural tube defects in several animal models. Our initial study provided the first evidence in humans that arsenic exposure contributes to spina bifida risk through its interaction with folate (Environmental Health, 2015). This work introduced arsenic as a potentially important modifier of micronutrient-based interventions and motivated a broader research agenda: determining the biological pathways through which arsenic and folate interact to affect neural tube defect risk, and testing whether those interactions can be overcome by higher doses of folic acid.

My epigenetic studies extended these observations. Mothers of children with spina bifida had distinct DNA methylation patterns compared with mothers of controls, enriched in genes involved in neural tube closure, folate metabolism, and arsenic metabolism (Environmental Health, 2026). In infants' dural tissue, arsenic exposure was associated with methylation changes in pathways implicated in neural tube closure, including Wnt signaling (Epigenetics, 2024). Using clinical trials and experimental models, the ViCTER consortium tests the hypothesis that high-dose folic acid can rescue arsenic-related epigenetic changes. In women with moderate arsenic exposure and a prior spina bifida-affected pregnancy, a three-month course of high-dose folic acid supplementation (5 mg/day) was shifted methylation at spina bifida-associated sites toward patterns observed in control mothers (Scientific Reports, 2026, in press). These findings provide some of the first molecular evidence that folic acid's protective effects involve DNA methylation and that folic acid may overcome arsenic's epigenetic effects.

Using the findings of epidemiology studies, we estimated that the prevalence of neural tube defects in high-arsenic settings was 35 per 10,000 births, which is more than six times the U.S. rate. We projected that arsenic filtration alone would reduce this rate by about a quarter, and that folic acid fortification of staple foods would reduce the rate by more than two-thirds. In June 2024, working with the Global Alliance for Improved Nutrition (GAIN), we presented these findings to Bangladesh's Ministry of Health and Family Welfare. The ministry subsequently issued seven resolutions, including recommendations for a national birth defect surveillance with an initial focus on high-arsenic areas, new dietary folate standards, a national media campaign, and a working group to develop folic acid fortification strategies for staple foods. The first folic acid-fortified flour reached consumers in December 2024.

A second line of research investigates translates studies in cell culture that showed arsenic could degrade CFTR, the chloride channel that is defective in cystic fibrosis. Our cross-sectional study among adults in Bangladesh that showed elevated sweat chloride, the diagnostic hallmark of cystic fibrosis, was found among adults with high arsenic exposure (New England Journal of Medicine, 2015). Subsequent studies showed that higher arsenic exposure was associated with nearly double the odds of airflow obstruction (PLoS One, 2025); we found no associations with measures of glucose homeostasis (Environmental Epidemiology, 2024). This work challenged the assumption that CFTR-related physiological abnormalities must arise from mutations in the CFTR gene. These findings support the hypothesis that environmental arsenic exposure contributes to a cystic fibrosis-like phenotype, especially in the lung. These studies also identify sweat chloride as an inexpensive and noninvasive marker of arsenic toxicity that warrants further clinical validation.

Publications